Effect of combined T- and B-cell depletion of allogeneic HLA-mismatched bone marrow graft on the magnitude and kinetics of Epstein-Barr virus load in the peripheral blood of bone marrow transplant recipients

Clinical Transplantation
Daorong LiuVictor Levitsky

Abstract

Recipients of T-cell-depleted bone marrow (BM) transplants (BMT) frequently develop Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) preceded by a rapid and prominent increase of EBV load in the peripheral blood. The level of this increase positively correlates with the incidence of PTLD. Using a semiquantitative PCR assay we compared the blood levels of EBV-DNA in patients transplanted with either T-cell or T- and B-cell-depleted human leukocyte antigen (HLA)-mismatched BM grafts. Combined T- and B-cell depletion correlated with significantly lower maximal levels of EBV load, which were reached with slower kinetics. These data indicate that B-cell depletion of BM can be used for prophylaxis of PTLD in BM transplant recipients and can affect the long-term balance between EBV and its host.

References

May 1, 1987·Pharmacology & Toxicology·S OvergaardF Nielsen-Kudsk
Jul 1, 1995·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·S TakizawaY Shinohara
Jul 1, 1995·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·P B KirschnerM F Beal
Oct 13, 1998·Immunity·G J BabcockD A Thorley-Lawson
Feb 23, 2000·Journal of Virology·M SavardJ Gosselin
Nov 28, 2002·Pediatric Transplantation·R D Holmes, R J Sokol
Mar 7, 2003·Bone Marrow Transplantation·A W LorenD E Tsai

❮ Previous
Next ❯

Citations

Jan 2, 2009·Journal of Hematology & Oncology·Xiao-jun Huang
Oct 2, 2007·Blood Cells, Molecules & Diseases·Franco AversaMassimo F Martelli
Feb 7, 2021·Annals of Hematology·Francesco Pegoraro, Claudio Favre

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.